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The study aimed to investigate the phytochemical and therapeutic effects of 
aerial parts of Vinca difformis for anticancer activity in normal and 
cyclophosphamide induced oxidative stress in mice brain. Aerial parts of Vinca 
difformis was extracted with ethanol:acetone mixture. Following 
extraction,extract was tested for the presences of phytochemical constituents 
and cyclophosphamide induced oxidative stress in mice brain. Presences of 
alkaloid, glycosides, steroids, phenolic compounds and volatile oils were 
identified in the extract. Among these total alkaloid content was 8% and 
0.348mg/mg gallic acid was obtained from the extract. Vinca difformis extract 
was effective as antioxidant to reduce the cyclophosphamide toxicity. Thus the 
results suggests that the aerial parts of Vinca difformis extract contains some 
active principles which may possess significant anti-cancer activity. 
INTRODUCTION 
 Cancer continues to be one of the major causes 
of mortality throughout the world. There will be an 
estimated 15 million new cases and 10 million new 
deaths in 2020, even if the current trends remain 
unchanged. 92 anticancer have been approved by the US 
Food and Drug Administration (FDA). Recently World 
Health Organization consultation considered only 17 
drugs and 2 antiemetic as high priority and 12 more to 
have some advantage in particular clinical settings. 
Although the development of new anticancer drug has 
improved survival in a few diseases such as childhood 
leukemia and testicular cancer, there is an urgent need to 
continue to develop new and improved agents, as well as 
to optimize the use of conventional drugs1. 
 Herbal drugs have been used since ancient times 
as medicines for the treatment of a range of diseases. 
Medicinal plants have played a key role in world health. 
In spite of the great advances observed in modern 
medicine in recent decades, plant still makes an 
important contribution to health care2. Over the past 
decade, interest in drugs derived from plants, especially 
the phytotherapeutics, has increased expensively. It is 
estimated that about 25% of all modern medicines are 
directly or indirectly derived from plants. In some 
particular cases, such as antitumoral and antimicrobial 
drugs 60% medicines currently available on the market 
and most of these in the late stages of clinical trials are 
derived from natural products, mainly from plants. The 
World Health Organization estimates that upto 80% of 
the world’s population relies on traditional medicinal 
system for some aspect of primary health care3. 
 Anticancer activity can be exerted through a 
wide variety of mechanisms mostly targeting DNA, 
directly or indirectly by anti-cancer agents. Anti-cancer 
agents are drugs used to control the growth of cancerous 
cells and/or treat malignancies by eradicating cancer 
cells without harming the normal cells4. An important 
characteristics of an anticancer drug is to able to induce 
cancer cell apoptosis and such differentiates between an 
anticancer drug and a toxic compound5. 
Cyclophosphamide is alkylating and Platinating agents 
which classify as cytotoxic agents. 
 The genus Vinca (Apocyanaceae) is an evergreen 
shrubs or herbaceaous perennials, native to western 
Europe. Vinca difformis known commonly as 
intermediate periwinkle. There are at least 86 alkaloids 
extracted from plants in the Vinca genus.[12] The 
chemotherapy agent vincristine is extracted from 
Vincarosea (current name Catharanthus roseus), and is 
used to treat some leukemias, lymphomas, and childhood 
cancers, as well as several other types of cancer and 
some non-cancerous conditions. Vinblastine is a chemical 
analogue of vincristine and is also used to treat various 
forms of cancer. Dimeric alkaloids such as vincristine and 
vinblastine are produced by the coupling of smaller 
indole alkaloids such as vindoline and catharanthine. In 
addition, the nootropic agent Vincamine is derived 
from Vinca minor11. The present investigation was 
designed for Phytochemical and Cyclophosphamide 
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MATERIALS AND METHODS 
 
Collection of Plant material 
 The aerial part of vinca difformis was collected 
from garden of Cagliari, Italy and powdered using 
grinder mill. The powdered drug packed in a paper bags 
and stored in air tight container until use. 
Authentification 
 The botanical identity was confirmed by 
Universitadeglistudi di Cagliari, Dipartimento di 
scienzebotaniche, Italy, the voucher specimen number is 
925/B. 
Preparation of extracts 
 The powdered drug was extracted with ethanol: 
acetone 1:1 by maceration. after completion of extraction 
solvent was recovered and the saturated solvent was 
dried over water bath at 40-50°C. The semisolid paste 
formed is transferred to petri plates and kept in hot air 
oven at 60°C for further drying and stored in air tight 
container and kept at 2-8°C for further use. 
PHYTOCHEMICAL SCREENING6 
 The freshly prepared crude extracts of the aerial 
parts of Vinca difformis were qualitatively tested for the 
presences of alkaloids, Tannins and Phenolic compounds, 
Flavanoids, Steroids, Glycosides, Saponins, Proteins and 
Amino acids. Total alkaloidal and Phenolic content was 
also determined. 
EXPERIMENTAL ANIMALS 
 Male Swiss albino mice 25-30gm of avg. wt. have 
been used. The animals maintained under standard 
environmental conditions had free access to standard 
diet and water ad libitum. Mice were housed in groups of 
six per cage. All the animals were maintained under 
standard conditions; that is room temperature 26±1°C, 
relative humidity 45-55% and 12:12 hrs light-dark cycle. 
The cages were maintained clean, and all experiments 
were conducted between 9 am and 4 pm. 
Acute Toxicity Study7 
 Swiss Albino mice (25 - 30 gm weight) were 
used for acute oral toxicity study. The study was carried 
out as per the guidelines set by OECD 425 and animals 
were observed for mortality and behavioral changes. 
Ethical Approval 
 The experimental protocols were approved by 
the Institutional Animal Ethics Committee (IAEC).All the 
experiments were conducted according to the guidelines 
of Committee for the Purpose of Control and Supervision 
of Experiments on Animals (CPCSEA). 
PHARMACOLOGICAL SCREENING 
Anti-Cancer activity of Vinca difformis against 
cyclophosphamide induced oxidative stress in mice 
brain. 
IN VIVO STUDY-BIOASSAY8 
 Mice weighing (25-30gm) was acclimatizes for 2 
weeks. 
 Mice was divided into three groups. 
 Group 1 (control) was feed basal diet (corn flour 
67%, ground nut cake 14%, fish meal 5%, ground 
nut oil 10% and vitamin mineral). 
 Group 2 was feed basal diet (corn flour 67%, 
ground nut cake14%, fish meal 5%, ground nut oil 
10% and vitamin mineral). 
 Group 3 was feed with basal diet with extract. 
 The rats in groups 2-3 was treated with 
cyclophosphamide by i.p (75mg/kg body weight). 
 The malonoaldehyde content of the brain was 
determined and serum glutamate oxaloacetate 
transferase (sgopt), glutamatepyruvatetransferase 
(sgpt) was determined by diagnostic kits. 
PREPARATION OF TISSUE HOMOGENATE 
 Rats was decapitated and its brain was removed. 
 The tissue was homogenized in cold saline 
(1/10w/v) and homogenizes in Teflon glass at 
1200rpm. 
 Centrifugation for 10min at 3000rpm. 
 S.I fraction (tissue homogenate) 
LIPID PEROXIDATION ASSAY9 
 0.2ml tissue homogenate add 0.2ml sodium 
doudecylsulphate (8%) add 1.5% acetic acid add 
1.5ml 8% thiobarbituric acid (8%). 
 Makeup volume to 4ml with distilled water. 
 Heat for 1hrs at 95°C on heating mantle. 
 Cool and add1ml water and add 5ml 
butanol:pyridine (15:1) 
 Shake using vortex shaker for 5min and centrifuge 
at 4000rpm foe 10 min. 
 Absorbance at 532nm on spectrophotometer 
.GLUTATHIONE (GSH) DETERMINATION10 
 Take 0.05ml of supernatant and added 0.2ml of 
DTNB Stock and 0.4ml of 1M Tris (PH 8). Then add 
3.350ml distilled water and put for incubation for 5min 
and after took absorbance at 412nm with blank. 
SGOT DETERMINATION 
Reagent Composition 
Reagent No. Reagent Composition 
1. Buffer Tris buffer(Ph 7.8), MDH,LD 
L-Aspartate 
2. Substrate α –ketoglutarate, NADH 
Procedure 
 Add reagent 2 to reagent 1 in 1:4 ratio. Pipette 
into tube marked serum/plasma 100µl and working AST 
reagent 1000µl, mix well and aspirate immediately for 
 George Mathew et al. Phytochemical Investigation and Anti-Cancer Activity of Aerial Parts of Vinca Difformis 
AYUSHDHARA | November - December 2015 | Vol 2 | Issue 6  406 
measurement. Program the analyser with purified water 
and read the absorbance after 60sec.repeat reading after 
every 30sec,upto 120sec. at 340nm wavelength. 
Determine the mean absorbance change per min. 
AST activity (IU/L) = A/minute*Kinetic factor 
Where A/minute=change in absorbance per minute. 
Kinetic factor(K)= 1768 
SGPT Determination 
Reagent composition 
Reagent No. Reagent Composition 
1. Buffer Tris buffer (ph 7.8), LD 
L-Alanine 
2. Substrate α – ketoglutarate NADH 
 Add reagent 2 to reagent 1 in 1:4 ratio. Mix 
serum/plasma 100µl to working AST reagent 1000µl and 
aspirate immediately for measurement. Programme the 
analyser as per assay parameters, Blank the analyser 
with purified water. Read the absorbance after 60sec. 
repeat reading after every 30sec,upto 120sec. at 340nm 
wavelength. Determine the mean absorbance change per 
min. ( A/minute) 
AST activity (IU/L) = A/minute*Kinetic factor 
Where A/minute=change in absorbance per minute. 
Kinetic factor (K)= 1768. 
Statistical Analysis 
 Statistical analysis was carried out using primer 
of Bio-statistical software. All results were expressed as 
mean ±standard error mean (SEM). Data were analyzed 
using one-way ANOVA followed by Bonferroni t-Test. In 
the entire tests the criterion for statistical significance 
was P‹ 0.05. 
RESULTS 
PHYTOCHEMICAL ANALYSIS 
 The results of the chemical tests performed in 
the screening, revealed the presences of flavonoids, 
alkaloids, tannins, glycosides, saponins, terpenoid in the 
extract of aerial parts of Vinca difformis. 
1. Colour – Grayish Black 
2. Consistency – Solid Powder 
3. Odour – Characteristic 
4. Percentage yield – 5.43% 
Table 1:Phytochemical analysis of aerial parts of Vinca difformis 
Sl.No. Test Inference 
Class : Carbohydrate 
1 Molish test + 
2 Iodine test + 
3 Benedict test + 
4 Inversion test + 
Class : Alkaloid 
1 Dragendroff test + 
2 Mayer test + 
3 Hager test + 
4 Wagner test + 
Class : Gycosides 
1 Keller-Killani test + 
2 Foam test + 
3 Haemolytic activity + 
4 Odour set + 
5 Alkaline test + 
6 Filter paper test + 
Class : Flavanoids 
1 Shinoda test + 
Class: Tannin and Phenolic Compounds 
1 Fecl3 5% + 
2 Lead acetate solution + 
3 Gelatin solution + 
4 Acetic acid solution + 
5 Potassium dichromate + 
6 Dil. Iodine solution + 
7 Dil. Nitric oxide + 
8 Mirror test + 
9 Dil.Potassium Permaganate + 
Class : Steroid 
1 Salkowaski Reaction + 
2 Libermann-burchad reaction + 
Class : Volatile Oils 
1 Odour test + 
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2 Filter paper test + 
3 Solubility test + 
Total Alkaloidal Determination 
Total Extract Weight 250 mg 
Total Alkaloid Dry Weight 20mg 
Percentage of Total Alkaloid Content 8 % 
Total Phenolic Content Determination 
Absorbance of Sample 0.921 
Sample Amount 1ml 
Concentration of Sample 100mg/ml 
Standard Curve Equation Y = 0.026X + 0.019 
Here X = Gallic acid conc.(µg/ml) 
Y = Absorbance 
Total Phenolic Content 0.348 mg/mg Gallic acid equivalent. 
Acute oral toxicity 
 Acute oral toxicity studies revealed the non-toxic nature of the Vinca difformis. The extract of Vinca difformis 
did not show any sign and symptoms of toxicity and mortality up to 2000 mg/kg dose after fourteen days of study. This 
indicates that the extracts were found to be safe up to the dose levels studied. Since, all the animals survived at a dose 
of 2000 mg/kg body weight, the LD50 of the extract will be >2000 mg/kg body weight. No major behavioural changes 
were observed during the period of study. Therefore 1/10th and 1/5thof the maximum tolerated safe dose was selected 
for further pharmacological activity. 
Anti-Cancer activity 
Cyclophosphamide induced Oxidative stress  
The extract treated showed a significant protection as compared to cyclophosphamide groups. 
Group Biochemical parameters 
  LPO (nM/mg protein) GSH (nmg/mg) GPT (IU/ml) GOT (IU/ml) 
Control 3806±81.33 2315±116.6 1.989±0.4232 6.63±1.111 
Cyclophosphamide 4970.16±61.62** 561.525±1977** 14.144±0.6251** 42.211±1.88** 
Drug+ 
Cyclophosphamide 
4198.75±63.27** 2822.4±26.84** 9.724±1.488** 15.028±3.405* 
Values are expressed as Mean ± SEM, for 4 animals, **P<0.05, significantly when compared with control group. 
DISCUSSION 
 The results of the present study demonstrated 
that the extract of Vinca difformis possessed alkaloid, 
carbohydrate, glycoside, steroids, phenolic compounds 
and volatile oils but amino acid, protein and 
anthraquinone type glycoside is absent. The chemical 
constituent flavanoids are responsible for anticancer 
activity. The total alkaloid content was 8% in extract 
ethanol/acetone(1:1) solvent system. Among these V.D.E. 
contained 0.348mg/mg Gallic acid equivalent phenolic 
compound. 
 Phenolics are diverse secondary metabolites 
abundant in plant tissues. Polyphenols possess ideal 
structural chemistry for radial scavenging activity 81. 
The LPO showed that there is a significance differences 
between the control and cyclophosphamide treated 
groups. Cyclophosphamide causes GSH depletion in brain 
and the extract protect against cyclophosphamide 
toxicity and increases the GSH level. In GPT the 
protection against liver toxicity were assesses on 
different parameters. The differences showed that drug 
protects the liver from cyclophosphamide induced 
toxicity but the drug has no capacity to reduce the level. 
Level of GOT in cyclophosphamide group was 
significantly high as compared to that of vehicle treated. 
On treatment with extract it was observed the extract 
decreased the elevated level of GOT as compared to 
cyclophosphamide only treated group. Thus the extract is 
potent in protecting the hepatic cells by the damaged 
caused by cyclophosphamide. 
CONCLUSION 
 In the present study Vinca difformis extract 
showed significant protection from cyclophosphamide 
induced toxicity in mice brain by reducing LPO level in 
brain and reducing the GPT and GOT level in serum and 
increasing the GSH level in mice brain. Raising the level 
of all three parameters showed the toxicity phenomena 
in response to oxidative stress and depletion of GSH in 
brain indicates oxidative stress. So ,on the basis of result 
it is concluded that Vinca difformis extract possessed 
antioxidant activity and it might be beneficial for 
protecting brain from oxidative damage caused by 
cyclophosphamide. Due to its antioxidant potential the 
anticancer activity was tested because a good antioxidant 
may be anticancer agent. 
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